Nevro (NVRO) could be a solid choice for investors given its ... side analysts covering the stock -- for the current and following years is tracked by the system. The power of a changing earnings ...

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the ...

Analysts at StockNews.com Give Nevro (NYSE:NVRO) a Hold Rating ...

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the ...

The company started 2025 on a solid note, driven by a decent guidance for the year, but a deal for loss-making Nevro creates some discomfort among investors. All this makes me intrigued to watch ...

Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

The CEO of Globus Medical said the deal will enable the Audubon company to expand into new markets for future growth.